SEC Form 4 · accession 0000899243-16-021118
Aimmune Therapeutics, Inc. · AIMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick G Enright
Director
Period of report
May 25, 2016
Accepted (ET)
May 27, 2016 · 4:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par valueF1 | holding | — | — | — | 7,513,134 | I | By: Longitude Venture Partners II, L.P. |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $15.40 | May 25, 2016 | A | 19,755 | A | — | May 25, 2026 | Common Stock | 19,755 | 19,755 | D |
Explanation of responses
- F1The shares are held by Longitude Venture Partners II, L.P. ("Longitude Venture II"). Longitude Capital Partners II, LLC ("Longitude Capital II") is the general partner of Longitude Venture II and may be deemed to have sole voting, investment and dispositive power over the shares held by Longitude Venture II. Patrick G. Enright is a managing member of Longitude Capital II and in his capacity as such may be deemed to exercise shared voting and investment power over the shares held by Longitude Venture II. Mr. Enright disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
- F2The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2017 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.